G-CSF and GM-CSF in Neutropenia

G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantat...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) 2015-08, Vol.195 (4), p.1341-1349
Main Authors: Mehta, Hrishikesh M, Malandra, Michael, Corey, Seth J
Format: Article
Language:English
Subjects:
Granulocyte Colony-Stimulating Factor - metabolism
Granulocyte Colony-Stimulating Factor - therapeutic use
Granulocyte-Macrophage Colony-Stimulating Factor - metabolism
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Humans
Neutropenia - drug therapy
Neutropenia - etiology
Neutropenia - metabolism
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias. Clinically significant neutropenia, rendering an individual immunocompromised, occurs when their number is 20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation. Because of its promotion of APC function, GM-CSF is being evaluated as an immunostimulatory adjuvant in a number of clinical trials. More than 20 million persons have benefited worldwide, and >$5 billion in sales occur annually in the United States.
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.1500861